Interleukin-6 - Wyeth

Drug Profile

Interleukin-6 - Wyeth

Alternative Names: BSF-2; ILS 969; SDZ ILS 969

Latest Information Update: 08 Feb 2006

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Wyeth
  • Class Antineoplastics; Interleukins
  • Mechanism of Action Interleukin stimulants; Natural killer cell stimulants; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Malignant melanoma; Myeloid leukaemia; Ovarian cancer; Preleukaemia; Renal cancer; Solid tumours; Thrombocytopenia

Most Recent Events

  • 08 Feb 2006 No development reported - Phase-I for Preleukaemia in USA (unspecified route)
  • 08 Feb 2006 No development reported - Phase-I for Solid tumours in USA (IV-infusion)
  • 08 Feb 2006 No development reported - Phase-II for Malignant melanoma in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top